Background Hyperglycemia-induced oxidative stress plays a central role in the development of diabetic myocardial complications. Adiponectin (APN), an adipokine with anti-diabetic and anti-ischemic effects, is decreased in diabetes. It is unknown whether or not antioxidant treatment with N-acetylcysteine (NAC) and/or allopurinol (ALP) can attenuate APN deficiency and myocardial ischemia reperfusion (MI/R) injury in the early stage of diabetes. Methodology/Principal Findings Control or streptozotocin (STZ)-induced diabetic rats were either untreated (C, D) or treated with NAC (1.5 g/kg/day) or ALP (100 mg/kg/day) or their combination for four weeks starting one week after STZ injection. Plasma and cardiac biochemical parameters were measured after the completion of treatment, and the rats were subjected to MI/R by occluding the left anterior descending artery for 30 min followed by 2 h reperfusion. Plasma and cardiac APN levels were decreased in diabetic rats accompanied by decreased cardiac APN receptor 2 (AdipoR2), reduced phosphorylation of Akt, signal transducer and activator of transcription 3 (STAT3) and endothelial nitric oxide synthase (eNOS) but increased IL-6 and TNF-α (all P<0.05 vs. C). NAC but not ALP increased cardiac APN concentrations and AdipoR2 expression in diabetic rats. ALP enhanced the effects of NAC in restoring cardiac AdipoR2 and phosphorylation of Akt, STAT3 and eNOS in diabetic rats. Further, NAC and ALP, respectively, decreased postischemic myocardial infarct size and creatinine kinase-MB (CK-MB) release in diabetic rats, while their combination conferred synergistic protective effects. In addition, exposure of cultured rat cardiomyocytes to high glucose resulted in significant reduction of cardiomyocyte APN concentration and AdipoR2 protein expression. APN supplementation restored high glucose induced AdipoR2 reduction in cardiomyocytes. Conclusions/Significance NAC and ALP synergistically restore myocardial APN and AdipoR2 mediated eNOS activation. This may represent the mechanism through which NAC and ALP combination greatly reduces MI/R injury in early diabetic rats.
References
[1]
Petrii VV, Mikova NV, Makolkin VI (2007) Correction of episodes of transitory myocardial ischemia with trimetazidine in patients with ischemic heart disease combined with type 2 diabetes mellitus. Kardiologiia 47: 22–25.
[2]
Takimoto E, Kass DA (2007) Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49: 241–248.
[3]
Cuzzocrea S, Riley DP, Caputi AP, Salvemini D (2001) Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 53: 135–159.
[4]
Gerstein HC, Bosch J, Pogue J, Taylor DW, Zinman B, et al. (1996) Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation Diabetes Care 19: 1225–1228.
[5]
Hajjar RJ, Leopold JA (2006) Xanthine oxidase inhibition and heart failure: novel therapeutic strategy for ventricular dysfunction? Circ Res 98: 169–171.
[6]
Takano H, Zou Y, Hasegawa H, Akazawa H, Nagai T, et al. (2003) Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 5: 789–794.
[7]
Guo Z, Xia Z, Jiang J, McNeill JH (2007) Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol 292: H1728–1736.
[8]
Desco MC, Asensi M, Marquez R, Martinez-Valls J, Vento M, et al. (2002) Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 51: 1118–1124.
[9]
Rajesh M, Mukhopadhyay P, Batkai S, Mukhopadhyay B, Patel V, et al. (2009) Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med 13: 2330–2341.
[10]
Kamigaki M, Sakaue S, Tsujino I, Ohira H, Ikeda D, et al. (2006) Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 339: 624–632.
[11]
Ouchi N, Walsh K (2007) Adiponectin as an anti-inflammatory factor. Clin Chim Acta 380: 24–30.
[12]
Pajvani UB, Scherer PE (2003) Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 3: 207–213.
[13]
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595–1599.
[14]
Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, et al. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11: 1096–1103.
[15]
Tao L, Gao E, Jiao X, Yuan Y, Li S, et al. (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115: 1408–1416.
[16]
Hattori Y, Suzuki M, Hattori S, Kasai K (2003) Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 46: 1543–1549.
[17]
Nagareddy PR, Xia Z, McNeill JH, Macleod KM (2005) Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol.
[18]
Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, et al. (2005) A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism 54: 194–199.
[19]
Xia Z, Kuo KH, Nagareddy PR, Wang F, Guo Z, et al. (2007) N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 73: 770–782.
[20]
Karwinski W, Garcia R, Helton WS (1994) Allopurinol dose is important for attenuation of liver dysfunction after normothermic ischemia: correlation between bile flow and liver enzymes in circulation. Res Exp Med (Berl) 194: 321–327.
[21]
Guo ZX, Xia ZY, Jiang JH, McNeill JH (2007) Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. American Journal of Physiology-Heart and Circulatory Physiology 292: H1728–H1736.
[22]
de Waard MC, van der Velden J, Boontje NM, Dekkers DH, van Haperen R, et al. (2009) Detrimental effect of combined exercise training and eNOS overexpression on cardiac function after myocardial infarction. Am J Physiol Heart Circ Physiol 296: H1513–1523.
[23]
Aime S, Gianolio E, Arena F, Barge A, Martina K, et al. (2009) New cyclodextrin dimers and trimers capable of forming supramolecular adducts with shape-specific ligands. Org Biomol Chem 7: 370–379.
[24]
Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, et al. (2004) Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62: 74–85.
[25]
Jamnicki-Abegg M, Weihrauch D, Chiari PC, Krolikowski JG, Pagel PS, et al. (2007) Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection. J Cardiovasc Pharmacol 50: 670–676.
[26]
Ding G, Qin Q, He N, Francis-David SC, Hou J, et al. (2007) Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J Mol Cell Cardiol 43: 73–84.
[27]
Hoo RL, Chow WS, Yau MH, Xu A, Tso AW, et al. (2007) Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. Arterioscler Thromb Vasc Biol 27: 2777–2782.
[28]
Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, et al. (2007) Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 56: 1387–1394.
[29]
Shoji T, Shinohara K, Hatsuda S, Kimoto E, Fukumoto S, et al. (2005) Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 54: 330–334.
[30]
Guo Z, Xia Z, Yuen VG, McNeill JH (2007) Cardiac expression of adiponectin and its receptors in streptozotocin-induced diabetic rats. Metabolism 56: 1363–1371.
[31]
Xi W, Satoh H, Kase H, Suzuki K, Hattori Y (2005) Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 332: 200–205.
[32]
Thule PM, Campbell AG, Kleinhenz DJ, Olson DE, Boutwell JJ, et al. (2006) Hepatic insulin gene therapy prevents deterioration of vascular function and improves adipocytokine profile in STZ-diabetic rats. Am J Physiol Endocrinol Metab 290: E114–E122.
[33]
Sun J, Xu Y, Dai Z, Sun Y (2009) Intermittent high glucose stimulate MCP-l, IL-18, and PAI-1, but inhibit adiponectin expression and secretion in adipocytes dependent of ROS. Cell Biochem Biophys 55: 173–180.
[34]
Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, et al. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10: 1384–1389.
[35]
Hajri T, Tao H, Wattacheril J, Marks-Shulman P, Abumrad NN (2010) Regulation of adiponectin production by insulin: Interactions with tumor necrosis factor-alpha and interleukin-6. Am J Physiol Endocrinol Metab.
[36]
Aldhahi W, Hamdy O (2003) Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 3: 293–298.
[37]
Suzuki T, Naka A, Kimura H (2009) Effects of uric acid on nitrosation of N-acetylcysteine by diethylamine NONOate and N-acetyl-N-nitrosotryptophan. Chemical & pharmaceutical bulletin 57: 736–739.
[38]
Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731–737.
[39]
Tilg H, Wolf AM (2005) Adiponectin: a key fat-derived molecule regulating inflammation. Expert Opin Ther Targets 9: 245–251.
[40]
Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, et al. (2004) Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 40: 177–184.
[41]
Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762–769.
[42]
Pineiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, et al. (2005) Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579: 5163–5169.
[43]
Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439–451.
[44]
Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, et al. (2004) Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279: 30817–30822.
[45]
de Oliveira C, de Mattos AB, Biz C, Oyama LM, Ribeiro EB, et al. (2011) High-fat diet and glucocorticoid treatment cause hyperglycemia associated with adiponectin receptor alterations. Lipids Health Dis 10: 11.
[46]
Cai XJ, Chen L, Li L, Feng M, Li X, et al. (2010) Adiponectin inhibits lipopolysaccharide-induced adventitial fibroblast migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS pathway. Mol Endocrinol 24: 218–228.
[47]
Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774–785.
[48]
Shimano M, Ouchi N, Shibata R, Ohashi K, Pimentel DR, et al. (2010) Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 49: 210–220.
[49]
Dyck JR, Lopaschuk GD (2006) AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 574: 95–112.
[50]
Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, et al. (2002) Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol 92: 2475–2482.
[51]
Hopkins TA, Dyck JR, Lopaschuk GD (2003) AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart. Biochem Soc Trans 31: 207–212.
[52]
Chang J, Li Y, Huang Y, Lam KS, Hoo RL, et al. (2010) Adiponectin Prevents Diabetic Premature Senescence of Endothelial Progenitor Cells and Promotes Endothelial Repair by Suppressing the p38 MAP kinase/p16INK4A Signaling Pathway. Diabetes.
[53]
Amour J, Brzezinska AK, Weihrauch D, Billstrom AR, Zielonka J, et al. (2009) Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. Anesthesiology 110: 317–325.
[54]
Lecour S (2009) Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 47: 32–40.
[55]
Walsh K (2009) Adipokines, myokines and cardiovascular disease. Circ J 73: 13–18.
[56]
Liao W, Yu C, Wen J, Jia W, Li G, et al. (2009) Adiponectin induces interleukin-6 production and activates STAT3 in adult mouse cardiac fibroblasts. Biol Cell 101: 263–272.
[57]
Chen B, Wei J, Wang W, Cui G, Zhao Y, et al. (2009) Identification of signaling pathways involved in aberrant production of adipokines in adipocytes undergoing oxidative stress. Arch Med Res 40: 241–248.
[58]
Suleman N, Somers S, Smith R, Opie LH, Lecour SC (2008) Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 79: 127–133.
[59]
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730–1737.
